Drug Metabolism in Drug Design and Development Basic Concepts and Practice

(nextflipdebug2) #1

clearance; US. Pat. Appl. Publ. 32 pp., Cont.-in-part of U.S. Ser. No. 815,300.
USA,2002.
Fotoohi AK, Lindqvist M, Peterson C, Albertioni F. Involvement of the concentrative
nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance
of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun
2006;343:208–215.
Garrigues A, Nugier J, Orlowski S, Ezan E. A high-throughput screening microplate
test for the interaction of drugs with P-glycoprotein. Anal Biochem 2002;305:106–
114.
Gati WP, Paterson ARP, Belch AR, Chlumecky V, Larratt LM, Mant MJ, Turner AR.
Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to
cytarabine (araC). Leuk Lymphoma 1998;32:45–54.
Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia
in renal transplant recipients taking cyclosporine. Transplantation 1996;62:1559–
1564.
Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J
Bioenerg Biomembr 2001;33:453–458.
Gottesman MM, Pastan I, Ueda K.Methods of inducing multidrug resistance in
mammalian cells using vectors carrying the human MDR1 gene; U.S. 11 pp.,
(United States Dept. of Health and Human Services, USA) 1999.
Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by
luminalR-verapamil. Clin Pharmacol Ther 1999;66:239–245.
Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer
HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
[erratum appears in J Clin Invest 2002 Aug;110(4):571]. J Clin Invest 1999a;104:147–153.
Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, Zundler J,
Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and
rifampin. J Clin Invest 1999b;104:147–153.
Grem JL. Biochemical modulation of fluorouracil by dipyridamole: preclinical and
clinical experience. Semin Oncol 1992;19:56–65.
Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft
gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the
effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol
2001;57:115–121.
Gupta SK, Bakran A, Johnson RW, Rowland M. Cyclosporin-erythromycin
interaction in renal transplant patients. Br J Clin Pharmacol 1989;27:475–481.
Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, Batra V.
Pharmacokinetic and safety profile of desloratadine and fexofenadine when
coadministered with azithromycin: a randomized, placebo-controlled, parallel-group
study. Clin Ther 2001;23:451–466.
Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast
cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI
tract. Biochem Pharmacol 2005;70:695–699.
Haimeur A, Conseil G, Deeley RG, Cole SPC. The MRP-related and BCRP/ABCG2
multidrug resistance proteins: biology, substrate specificity and regulation. Curr
Drug Metab 2004;5:21–53.


REFERENCES 189

Free download pdf